Effect of intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results

Acta Ophthalmologica

Volumn 88, Issue 5, 2010, Pages 594-600

  Leydolt, Christina ^a   Michels, Stephan ^b   Prager, Franz ^a   Garhoefer, Gerhard ^a   Georgopoulos, Michael ^a   Polak, Kaija ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

intravitreal bevacizumab; intravitreal injections; neovascular age related macular degeneration; OCT

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; GENTAMICIN; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EYE EXAMINATION; EYE FUNDUS; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINAL THICKNESS; RETREATMENT; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77954645507     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01485.x     Document Type: Article

References (47)

1. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, Hernandez-Rojas M, Quiroz-Mercado H Morales-Canton V (2006 Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 245 : 651 655.
2. Adamis AP, Aiello LP D'Amato RA (1999 Angiogenesis and ophthalmic disease. Angiogenesis 3 : 9 14.
3. Ahmadieh H, Taei R, Soheilian M et al. (2007 Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 7 : 10.
4. Algvere PV, Steen B, Seregard S Kvanta A (2008 A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86 : 482 489.
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA Giust MJ (2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 : 363 372.e365
6. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP & Noureddin BN (2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 : 1 9.
7. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF Noureddin BN (2007 Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125 : 1357 1361.
8. Blumenkranz MS, Bressler NM, Bressler SB et al. (2002 Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report no. 5. Arch Ophthalmol 120 : 1307 1314.
9. Bolz M, Michels S, Geitzenauer W, Prager F Schmidt-Erfurth U (2006 Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 91 : 785 789.
10. Brown DM Regillo CD (2007 Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144 : 627 637.
11. Chen E, Kaiser RS Vander JF (2007 Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 27 : 445 450.
12. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW Hickey-Dwyer M (2007 Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22 : 82 86.
13. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr. Scott IU (2006 Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 : 4569 4578.
14. Drexler W (2004 Ultrahigh-resolution optical coherence tomography. J Biomed Opt 9 : 47 74.
15. Emerson MV, Lauer AK, Flaxel CJ et al. (2007 Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration. Retina 27 : 439 444.
16. Fung AE, Rosenfeld PJ Reichel E (2006 The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 : 1344 1349.
17. Fung AE, Lalwani GA, Rosenfeld PJ et al. (2007 An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 : 566 583.
18. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM Fu A (2007 Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27 : 432 438.
19. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M Guyer DR (2004 Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 : 2805 2816.
20. Group MPS (1991 Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular photocoagulation study group. Arch Ophthalmol 109 : 1109 1114.
21. Group MPS (1994 Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular photocoagulation study group. Arch Ophthalmol 112 : 480 488.
22. Group TAP (1999 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117 : 1329 1345.
23. Hanley JA Lippman-Hand A (1983 If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 249 : 1743 1745.
24. Heier JS, Antoszyk AN, Pavan PR et al. (2006 Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113 : 633 642.
25. Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW Sadda SR (2007 Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology 115 : 347 354.
26. Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W Schmidt-Erfurth U (2006 Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26 : 877 881.
27. Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG Eter N (2008 Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246 : 17 25.
28. Mennel S, Callizo J, Schmidt JC Meyer CH (2007 Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 85 : 689 691.
29. Meyer CH, Mennel S, Schmidt JC Kroll P (2006 Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 90 : 1207 1208.
30. Michels S (2006 Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90 : 1333 1334.
31. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN Venkatraman AS (2005 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 : 1035 1047.
32. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD Venkatraman AS (2006 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 : 2002 2011.
33. Mulcahy MF Benson AB III. (2005 Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5 : 997 1005.
34. Owen CG, Fletcher AE, Donoghue M Rudnicka AR (2003 How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 87 : 312 317.
35. Pedersen R, Soliman W, Lund-Andersen H Larsen M (2007 Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85 : 526 533.
36. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU Schraermeyer U (2007 Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143 : 995 1002.
37. Pircher M, Gotzinger E, Findl O, Michels S, Geitzenauer W, Leydolt C, Schmidt-Erfurth U Hitzenberger CK (2006 Human macula investigated in vivo with polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci 47 : 5487 5494.
38. Rechtman E, Danis RP, Pratt LM Harris A (2004 Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88 : 344 347.
39. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider T Shams N (2008 Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 : 239 248.
40. Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006 Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 : 495 511.
41. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 : 331 335.
42. Rosenfeld P, Rich RM Lalwani GA (2006 Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19 : 361 372.
43. Schmidt-Erfurth U, Leitgeb RA, Michels S et al. (2005 Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 46 : 3393 3402. (Pubitemid 44264330)
44. Spaide RF, Sorenson J Maranan L (2003 Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 : 1517 1525.
45. Tomany SC, Wang JJ, Van Leeuwen R et al. (2004 Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 111 : 1280 1287.
46. ®) therapy versus photodynamic therapy plus intravitreal triamconolone for neovascular age-related macular degeneration. 6 months results of a prospective, randomized, controlled clinical study. Br J Ophthalmol 92 : 356 360.
47. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK Fastenberg DM (2006 Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26 : 994 998.